SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced that the number of shares and voting rights has increased by 2,883,725 following the completion of the directed issue of new shares resolved by the Board of Directors on March 2, 2026.

On March 2, 2026, SynAct announced that the Board of Directors had, by virtue of the authorization from the Annual General Meeting on May 27, 2025, resolved on a directed issue of 2,883,725 new shares. Consequently, as of March 31, 2026, the total number of registered shares in SynAct amounts to 56,213,968 and the total number of votes in SynAct amounts to 56,213,968.

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-03-31 10:00 CEST.

Attachments
Change in number of shares and voting rights in Synact Pharma AB

Läs mer på MFN